Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-08-16
S
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Steve Lee's research focuses on the biological mechanisms and clinical applications related to various cancers, with a particular emphasis on head and neck cancers and thyroid carcinoma. His work investigates the underlying biology of these diseases, including phenotypic features and the potential for targeted therapies. Lee has published research on the REASON score, an epigenetic and clinicopathologic tool developed to predict survival risk in early-stage oral squamous cell carcinoma, and has explored the role of neurotrophin pathway receptors in perineural invasion, metastasis, and pain associated with oral cancer. He also studies the use of brush swabs as a noninvasive method for epigenomic profiling in oral cancer and has investigated artificial intelligence-based signatures related to tobacco use in oral squamous cell carcinoma.
Beyond oncology, Lee's research interests extend to other medical and biological areas. He has contributed to studies on scapholunate reconstruction techniques in orthopedic surgery and has investigated the molecular monitoring of EHV-1 in horses. His recent work also includes exploring the diagnostic and management applications of artificial intelligence, specifically ChatGPT, within structured otolaryngology clinical scenarios. Lee leads a research group and has a significant publication record, evidenced by an h-index of 35 and over 4,900 citations, designating him as a highly cited researcher.
Metrics
- h-index: 35
- Publications: 190
- Citations: 4,976
Selected Publications
-
TCT-262 Five-Year Mortality Comparison of Left Ventricular Unloading Devices for Individuals with Cardiogenic Shock on VA-ECMO (2025)
Collaboration Network
Top Collaborators
Pedro A. Andrade Filho
Loma Linda University Medical Center (US)
18 shared publications
- Targeting Tumor Microenvironment Akt Signaling Represents a Potential Therapeutic Strategy for Aggressive Thyroid Cancer
- Tumor Cell Stemness and Stromal Cell Features Contribute to Oral Cancer Outcome Disparity in Black Americans
- Supplementary Figure 3A from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 3B from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 2 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Showing 5 of 18 shared publications
Christopher A. Lord
16 shared publications
- Supplementary Figure 3A from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 3B from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 2 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 1 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 4 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Showing 5 of 16 shared publications
Hyun-Bae Jie
16 shared publications
- Supplementary Figure 3A from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 3B from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 2 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 1 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 4 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Showing 5 of 16 shared publications
H. Carter Davidson
16 shared publications
- Supplementary Figure 3A from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 3B from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 2 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 1 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 4 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Showing 5 of 16 shared publications
Andrés López‐Albaitero
16 shared publications
- Supplementary Figure 3A from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 3B from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 2 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 1 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 4 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Showing 5 of 16 shared publications
Sandra P. Gibson
16 shared publications
- Supplementary Figure 3A from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 3B from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 2 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 1 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 4 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Showing 5 of 16 shared publications
William E. Gooding
16 shared publications
- Supplementary Figure 3A from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 3B from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 2 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 1 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 4 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Showing 5 of 16 shared publications
Soldano Ferrone
16 shared publications
- Supplementary Figure 3A from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 3B from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 2 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 1 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 4 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Showing 5 of 16 shared publications
Robert L. Ferris
16 shared publications
- Supplementary Figure 3A from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 3B from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 2 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 1 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 4 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Showing 5 of 16 shared publications
Raghvendra M. Srivastava
12 shared publications
- Supplementary Figure 3A from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 3B from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 2 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 4 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
- Supplementary Figure 5 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Showing 5 of 12 shared publications
Paul C. Walker
Loma Linda University Health Care (US)
8 shared publications
- The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma
- Neurotrophin Pathway Receptors NGFR and TrkA Control Perineural Invasion, Metastasis, and Pain in Oral Cancer
- Brush swab as a noninvasive surrogate for tissue biopsies in epigenomic profiling of oral cancer
- Artificial intelligence-based epigenomic, transcriptomic and histologic signatures of tobacco use in oral squamous cell carcinoma
- Dysphagia Severity and Outcomes Following Iatrogenic High Vagal Nerve Injury
Showing 5 of 8 shared publications
Chi T. Viet
Loma Linda University (US)
7 shared publications
- The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma
- Neurotrophin Pathway Receptors NGFR and TrkA Control Perineural Invasion, Metastasis, and Pain in Oral Cancer
- Brush swab as a noninvasive surrogate for tissue biopsies in epigenomic profiling of oral cancer
- Artificial intelligence-based epigenomic, transcriptomic and histologic signatures of tobacco use in oral squamous cell carcinoma
- Brush Swab As A Noninvasive Surrogate for Tissue Biopsies in Oral Cancer Patients To Develop Clinically Translatable Epigenetic Biomarkers
Showing 5 of 7 shared publications
Gary Yu
New York University (US)
7 shared publications
- The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma
- Neurotrophin Pathway Receptors NGFR and TrkA Control Perineural Invasion, Metastasis, and Pain in Oral Cancer
- Brush swab as a noninvasive surrogate for tissue biopsies in epigenomic profiling of oral cancer
- Artificial intelligence-based epigenomic, transcriptomic and histologic signatures of tobacco use in oral squamous cell carcinoma
- Brush Swab As A Noninvasive Surrogate for Tissue Biopsies in Oral Cancer Patients To Develop Clinically Translatable Epigenetic Biomarkers
Showing 5 of 7 shared publications
Kesava Asam
New York University (US)
7 shared publications
- The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma
- Neurotrophin Pathway Receptors NGFR and TrkA Control Perineural Invasion, Metastasis, and Pain in Oral Cancer
- Brush swab as a noninvasive surrogate for tissue biopsies in epigenomic profiling of oral cancer
- Artificial intelligence-based epigenomic, transcriptomic and histologic signatures of tobacco use in oral squamous cell carcinoma
- Brush Swab As A Noninvasive Surrogate for Tissue Biopsies in Oral Cancer Patients To Develop Clinically Translatable Epigenetic Biomarkers
Showing 5 of 7 shared publications
Carissa M. Thomas
University of Alabama at Birmingham (US)
7 shared publications
- The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma
- Neurotrophin Pathway Receptors NGFR and TrkA Control Perineural Invasion, Metastasis, and Pain in Oral Cancer
- Brush swab as a noninvasive surrogate for tissue biopsies in epigenomic profiling of oral cancer
- Artificial intelligence-based epigenomic, transcriptomic and histologic signatures of tobacco use in oral squamous cell carcinoma
- Brush Swab As A Noninvasive Surrogate for Tissue Biopsies in Oral Cancer Patients To Develop Clinically Translatable Epigenetic Biomarkers
Showing 5 of 7 shared publications
Similar Researchers
Based on overlapping research topics
Kyle P. Davis
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Machine Learning Applications
Retrospective Studies
Fraley, Patrick
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer-related molecular mechanisms research
Epigenetics and DNA Methylation
Marty Pagel
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Metabolomics and Mass Spectrometry Techniques
Machine Learning Applications
Stepan Melnyk
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Epigenetics and DNA Methylation
Metabolomics and Mass Spectrometry Techniques
Vural Emre
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Retrospective Studies
Medical Case Studies
Riley K Russo
University of Arkansas at Fayetteville
Cancer-related molecular mechanisms research
Retrospective Studies
Medical Case Studies